AMS/Reprogenesis tissue-engineered incontinence treatment slated for 1996 clinicals.
This article was originally published in The Gray Sheet
Executive Summary
REPROGENESIS/AMS CLINICAL STUDIES FOR TISSUE-ENGINEERED TREATMENTS for urinary stress incontinence and vesicouretal reflux are scheduled to begin in 1996, according to Reprogenesis parent Parker Medical. Pfizer subsidiary American Medical Systems and Reprogenesis recently entered agreements for the development of permanent tissue replacements for the treatment of urological disorders.